Dengue Clinical Trials | A Drug Pipeline Analysis Report 2024 | Takeda, Merck Sharp & Dohme, AbViro LLC, and others

United States, Nevada, Las Vegas, DelveInsight's 'Dengue Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Dengue therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dengue pipeline domain.
Request for a free sample report on Dengue Pipeline Insights 2024 @ https://www.delveinsight.com/report-store/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Dengue Pipeline Report
Over 20+ Dengue pipeline therapies are in various stages of development, and their anticipated acceptance in the Dengue market would significantly increase market revenue.
Leading Dengue companies developing novel drug candidates to improve the Dengue treatment landscape include Takeda, Merck Sharp & Dohme, AbViro LLC, and others.
Promising Dengue pipeline therapies in various stages of development include TAK003, V180, AV1, and others.
Dengue Overview
Dengue fever is a viral infection transmitted primarily by the Aedes mosquitoes, particularly Aedes aegypti and Aedes albopictus. Here's an overview covering its signs and symptoms, causes, diagnosis, and treatment options:

Dengue Signs and Symptoms:
1. Fever: Dengue typically begins with a sudden high fever, often reaching up to 104°F (40°C).

2. Severe headache: Intense headaches, often described as "breakbone fever" due to their severity, are common.

3. Pain behind the eyes: Pain in the eyes, especially when moving them, is another characteristic symptom.

4. Muscle and joint pain: Severe muscle and joint pain, leading to the term "bone-breaking fever."

5. Fatigue: Overwhelming fatigue and weakness are typical during the acute phase of the illness.

6. Skin rash: A rash may appear two to five days after the onset of fever, typically starting on the arms and legs and sometimes spreading to the rest of the body.

7. Mild bleeding: Some people may experience mild bleeding from the nose or gums.

Dengue Causes:
Dengue fever is caused by any one of four closely related dengue viruses (DEN-1, DEN-2, DEN-3, and DEN-4), which are part of the Flaviviridae family. The viruses are transmitted to humans through the bite of infected Aedes mosquitoes, primarily Aedes aegypti and Aedes albopictus. These mosquitoes become infected when they bite a person already infected with the virus.

Dengue Diagnosis:
1. Clinical evaluation: Based on symptoms, especially in areas where dengue is endemic, a doctor may suspect dengue fever.

2. Blood tests:
- NS1 antigen test: This test detects the presence of dengue virus proteins in the blood during the early stages of infection.
- Polymerase chain reaction (PCR) test: This test can detect the genetic material (RNA) of the dengue virus in the blood.
- IgM and IgG antibodies: Blood tests can detect these antibodies, which the body produces in response to the dengue virus. IgM antibodies typically appear first, followed by IgG antibodies.

Dengue Treatment Options:
1. Supportive care: There is no specific antiviral treatment for dengue fever. Treatment primarily focuses on supportive care to relieve symptoms and prevent complications:
- Pain relievers: Acetaminophen (paracetamol) is usually recommended to reduce fever and relieve pain. Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin, as they can increase the risk of bleeding.
- Fluid intake: Adequate hydration is crucial to prevent dehydration, especially if there is vomiting or diarrhea.
- Rest: Plenty of rest is essential during the acute phase of the illness.

2. Hospitalization: Severe cases of dengue fever, particularly dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), may require hospitalization for:
- Intravenous fluids: Fluids are given intravenously to maintain blood pressure and hydration.
- Monitoring: Close monitoring of vital signs, blood counts, and organ function is essential.

3. Prevention: Preventing mosquito bites is crucial in areas where dengue is endemic. This includes using mosquito repellents, wearing long sleeves and pants, using mosquito nets, and eliminating breeding sites around homes (stagnant water in containers).

Dengue Market Outlook:
Most people recover completely from dengue fever with supportive care. However, in severe cases, particularly in those with impaired immune systems or underlying health conditions, dengue can be life-threatening. Early detection and prompt medical attention can significantly improve outcomes.

Dengue Pipeline Analysis: Drug Profile
AV1: AbViro LLC
AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact. Currently Av1 is being studied in phase I in adult healthy individuals.
Discover more about the emerging Dengue drugs @ https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dengue Key Companies
Takeda
Merck Sharp & Dohme
AbViro LLC
Dengue Pipeline Therapies
TAK003
V180
AV1
Dengue Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Dengue Pipeline Report
Coverage: Global
Key Dengue Companies: Takeda, Merck Sharp & Dohme, AbViro LLC, and others
Key Dengue Pipeline Therapies: TAK003, V180, AV1, and others
Find out more about the Dengue treatment options in development @ https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Download free sample report @ https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight:

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.